When last we checked in with the psychedelic goings on at drug manufacturer Retrophin, the biotech’s board of directors had ousted its precocious founder and chief executive officer for alleged stock-related irregularities. Now the supposedly canned CEO says that he has done nothing seriously wrong, he’s still the boss, he’s still on the board, and he’s the victim of an unjustified putsch.
Investors seem understandably troubled. Retrophin’s stock was down nearly 2 percent at midday, trading at 10.79.
Help employers find you! Check out all the jobs and post your resume.
